Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: dates

Significant milestones achieved on all drug candidates in 2020 and financial visibility until 2022

20210310 Transgene Results 2020 EN

Published 10 March 2021
Categorized as 2021, Press release

Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences

20210302 – Transgene Scientific Conferences

Published 2 March 2021
Categorized as 2021, Invir.IO, Myvac, Press release

Transgene and BioInvent have enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors

20210301 – Transgene BT-001 FPI – EN

Published 1 March 2021
Categorized as 2021, BT-001, Invir.IO, Press release

Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs

Jérémy Béguin, et al. Sci Rep., January 26 2021 – Read the article Publication

Published 26 January 2021
Categorized as -others, 2021, Publication, TG6002

Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC

Adrian von Witzleben, et al. Front Oncol., January 26 2021 – Read the article Publication

Published 26 January 2021
Categorized as -others, 2021, Publication, TG4001

First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy

20210121 TG4050 1st patient HNSCC EN

Published 21 January 2021
Categorized as 2021, Myvac, Press release, TG4050

Transgene and BioInvent receive approval from ANSM to proceed with Phase I/IIa trial of anti-CTLA4-armed oncolytic virus BT-001 in solid tumors

20210119 – ANSM Approval BT-001 EN

Published 19 January 2021
Categorized as 2021, BT-001, Invir.IO, Press release

Transgene Appoints Gaëlle Stadtler as Director of Human Resources

20210114 Transgene – Appointment Gaelle Stadtler_EN

Published 14 January 2021
Categorized as 2021, Press release

Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors

20201221 – CTA Approval BT-001 – EN

Published 21 December 2020
Categorized as 2020, BT-001, Invir.IO, Press release

Transgene Announces Financial Calendar for 2021

20191217 Financial calendar 2021 EN

Published 17 December 2020
Categorized as 2020, Press release

Posts pagination

Newer posts Page 1 … Page 22 … Page 47 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu